Molnupiravir: A new candidate for COVID‐19 treatment

Pharmacology Research & Perspectives

Haleh Rezaee¹  Fariba Pourkarim²  Samira Pourtaghi‐Anvarian² 

[1] Department of Clinical Pharmacy Faculty of Pharmacy Tabriz University of Medical Sciences Tabriz Iran;Student Research Committee Faculty of Pharmacy Tabriz University of Medical Sciences Tabriz Iran;

关键词: antiviral drugs;    COVID‐19 treatment;    EIDD‐2801;    MK‐4482;    molnupiravir;    novel coronavirus disease 2019;   

DOI  :  10.1002/prp2.909

来源: DOAJ

【 摘 要 】

Abstract The novel coronavirus disease 2019 (COVID‐19) emerged in late December 2019 in china and has rapidly spread to many countries around the world. The effective pharmacotherapy can reduce the mortality of COVID‐19. Antiviral medications are the candidate therapies for the management of COVID‐19. Molnupiravir is an antiviral drug with anti‐RNA polymerase activity and currently is under investigation for the treatment of patients with COVID‐19. This review focuses on summarizing published literature for the mechanism of action, safety, efficacy, and clinical trials of molnupiravir in the treatment of COVID‐19 patients.

【 授权许可】

Unknown